Biologics in severe asthma : A pragmatic approach for choosing the right treatment for the right patient
(2023) In Respiratory Medicine 218.- Abstract
The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. We also focus on the role of biomarkers and treatable traits, including comorbidities, in the choice of asthma biologics, highlight which... (More)
The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. We also focus on the role of biomarkers and treatable traits, including comorbidities, in the choice of asthma biologics, highlight which treatments have been demonstrated to be steroid sparing in corticosteroid dependent asthma, and provide practical guidance that can drive shared decision making on treatment choice with patients. In addition, we summarize what is known to date regarding long-term safety of these drugs, and lastly, discuss future directions in biologics research.
(Less)
- author
- Rogers, Linda ; Jesenak, Milos ; Bjermer, Leif LU ; Hanania, Nicola A. ; Seys, Sven F. and Diamant, Zuzana LU
- organization
- publishing date
- 2023-11
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Asthma, Asthma management, Biologics, Biomarkers, Comorbidities, Type 2 inflammation
- in
- Respiratory Medicine
- volume
- 218
- article number
- 107414
- publisher
- Elsevier
- external identifiers
-
- pmid:37776915
- scopus:85173285834
- ISSN
- 0954-6111
- DOI
- 10.1016/j.rmed.2023.107414
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2023 The Authors
- id
- ced6f071-8a7b-41be-9b0a-24efd0ee7d49
- date added to LUP
- 2023-12-04 13:43:35
- date last changed
- 2024-04-17 09:51:58
@article{ced6f071-8a7b-41be-9b0a-24efd0ee7d49,
abstract = {{<p>The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. We also focus on the role of biomarkers and treatable traits, including comorbidities, in the choice of asthma biologics, highlight which treatments have been demonstrated to be steroid sparing in corticosteroid dependent asthma, and provide practical guidance that can drive shared decision making on treatment choice with patients. In addition, we summarize what is known to date regarding long-term safety of these drugs, and lastly, discuss future directions in biologics research.</p>}},
author = {{Rogers, Linda and Jesenak, Milos and Bjermer, Leif and Hanania, Nicola A. and Seys, Sven F. and Diamant, Zuzana}},
issn = {{0954-6111}},
keywords = {{Asthma; Asthma management; Biologics; Biomarkers; Comorbidities; Type 2 inflammation}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Respiratory Medicine}},
title = {{Biologics in severe asthma : A pragmatic approach for choosing the right treatment for the right patient}},
url = {{http://dx.doi.org/10.1016/j.rmed.2023.107414}},
doi = {{10.1016/j.rmed.2023.107414}},
volume = {{218}},
year = {{2023}},
}